Our view: Setbacks are costly but biotech industry copes
IN THIS ARTICLE
- Central Coast Topic
- Henry Dubroff Author
By Editorial board and Henry Dubroff Friday, July 19th, 2019
Amid a boom in the biotech industry in the Conejo Valley, comes a reminder that drug discovery is expensive and not risk-free. On July 11, Thousand Oaks-based Amgen and partners Novartis, another pharmaceuticals giant, and the Banner Alzheimer’s Institute abruptly halted clinical trials for CNP520, a drug that had shown promise for the prevention of…